Strategy Inc: first week of a sell signal, trading not recommended
Strategy Inc Class A enters its first week of a weekly sell signal. The structure is bearish, IQS at 73 out of 100 is in tension, but quality band flags trading as not recommended: opening a new short position carries elevated risk per our model.
Microsoft in transition: first window passed, next due at week 8
Microsoft is at week 7 of a buy signal with the first model reference already hit at week 6. The technical picture is in transition: IQS at 40, MACD deteriorating, the confirmation week suggested holding. Next window due at week 8.
Marvell Technology: runner at +194%, model coverage done, trailing stop active
Marvell Technology is at week 13 of a buy trade that has already cleared all 3 model targets. The 40% runner continues at +194% from entry, with the trailing stop on the Inversion Point. This week: a strong acceleration, but early exhaustion signals worth watching.
Moderna: coverage complete, the 40% runner holds on a double bottom
Moderna is at week 25 of a buy opened in the 29 area: model coverage is complete, the stop protects a 61% gain. The 40% runner continues on a double bottom in the 44 area, with momentum recovering but distribution still present.
Merck & Co.: Signal Holds, but the Confirmation Week Said It All
Merck & Co. is in week 2 of a buy signal, but the confirmation week closed bearish and the system has flagged an early exit warning. Weak conviction, IQS in ordinary phase, ranked 145th out of 161 in the category.
Trade in profit, stop at breakeven: 2 weeks to the first management window
Marathon Petroleum is at week 4 of a buy signal: the trade is up 7% and the stop has already been moved to breakeven. Two weeks remain to the first statistical management window, scheduled at week 6.